PCM
MIRM icon

Penn Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Penn Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.8M Sell
256,767
-25,151
-9% -$2.37M 1.84% 1
2025
Q4 		$22.3M Sell
281,918
-26,073
-8% -$1.87M 1.78% 3
2025
Q3 		$22.6M Sell
307,991
-34,265
-10% -$2.18M 1.74% 4
2025
Q2 		$17.5M Sell
342,256
-31,263
-8% -$1.39M 1.51% 17
2025
Q1 		$16.9M Buy
373,519
+95,092
+34% +$4.48M 1.64% 12
2024
Q4 		$11.5M Sell
278,427
-30,817
-10% -$1.28M 1.13% 42
2024
Q3 		$12.1M Buy
309,244
+68,093
+28% +$2.72M 1.11% 42
2024
Q2 		$8.26M Sell
241,151
-4,545
-2% -$119K 0.78% 62
2024
Q1 		$6.18M Sell
245,696
-32
-0% -$880 0.55% 71
2023
Q4 		$7.26M Sell
245,728
-242
-0.1% -$7.32K 0.67% 68
2023
Q3 		$7.78M Buy
245,970
+6,696
+3% +$183K 0.8% 62
2023
Q2 		$6.19M Buy
+239,274
New +$6.36M 0.6% 68

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Penn Capital Management's MIRM Position: Q1 2026 in Review

Penn Capital Management reduced its Mirum Pharmaceuticals (MIRM) stake by 8.9% in Q1 2026, selling an estimated $2.37M and leaving 256,767 shares worth $23.8M. The position accounts for 1.84% of the portfolio, ranked #1.

Penn Capital Management first reported a position in MIRM in Q2 2023 and has held it in 12 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Penn Capital Management held 256,767 shares of Mirum Pharmaceuticals worth $23.8M as of Q1 2026.
  • Penn Capital Management sold 25,151 Mirum Pharmaceuticals shares in Q1 2026, an estimated $2.37M.
  • Mirum Pharmaceuticals made up 1.84% of Penn Capital Management's portfolio in Q1 2026, its #1 holding.
  • Penn Capital Management first reported a position in Mirum Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Penn Capital Management's 13F filing for Q1 2026, filed 7 May 2026.